Wednesday, January 30th, 2013, 9:30-10:25am
With almost a decade under its belt, the BIO Asia International Conference has been accelerating the pathway to partnerships in Asia since the conference's inception. The world of biotech, however, doesn't quite paint the same picture as in the past. How has the biopharma industry changed over the last decade? What types of partnerships both, domestic and cross-border are fueling the industry? A new crop of biopharma BD executives are entering the market--how will their perspectives and experience change the way Asia looks at the industry and partnering trends? Senior executives in Asian biopharma both seasoned and new will present a fresh look on changing biopharma landscape in Asia.
- David Flores, President & CEO, BioCentury Publications
- Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Development and Medical, Merck Serono
- Rami Suzuki, PhD, Group Officer, Executive Director, Business Development, Eisai Co. Ltd.
- Augustine Yee, Asia Pacific Head of Regional and Corporate Business Development, AstraZeneca
David Flores has devoted more than 20 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. Mr. Flores is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, Mr. Flores and BioCentury Co-Founder, Chairman & Editor-in-Chief Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, California, citing BioCentury’s ongoing contributions to the industry.
Annalisa Jenkins, MBBS, MRCP
Annalisa Jenkins, MBBS, MRCP, is Executive Vice President, Head of Global Development and Medical for Merck Serono. Dr. Jenkins is also a member of the Pharmaceutical Executive Committee.
Prior to joining Merck Serono, Dr. Jenkins was Senior Vice President, Global Medical Affairs at Bristol-Myers Squibb (BMS). She started with BMS in 1997 as a Cardiovascular Medical Advisor based in the UK. In 2000, she moved to Australia to serve as Executive Medical Director for Australia and New Zealand, subsequently leading the Medical Division across Asia Pacific and Latin America.
In 2002, Dr. Jenkins moved to BMS’s major R&D site in Princeton, New Jersey, to oversee the company’s International Medical Division. After three years in this role, she was appointed Chief Medical Officer (CMO) for Europe, Middle East and Africa, subsequently taking on the position of Senior Vice President and CMO responsible for the Americas and the Development Teams.
Annalisa Jenkins began her career as a Medical Officer with the British Royal Navy, and served with the Minesweeper Squadron during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. She graduated in Medicine from St Bartholomew’s Hospital London and trained in Cardiology with the UK National Health Service.
Rami Suzuki, PhD
Rami Suzuki, PhD, heads corporate business development efforts at the Tokyo headquarters of Eisai Co., Ltd. Before joining Eisai, she worked for a venture capital fund, specializing in European life science opportunities. Dr. Suzuki obtained her PhD in Medicine at Ludwig Institute of Cancer Research, University College London, and her post-doctoral work focused on breast cancer at Imperial College, London.
Augustine Yee is based in AstraZeneca’s Asia Pacific headquarters located in Shanghai, China. He is currently Head of Asia Pacific Regional and Corporate Business Development for AstraZeneca and the acting Vice President of Business Development for AstraZeneca China. Augustine joined AstraZeneca in 2007 as Senior Director in the Global Strategic Planning and Business Development group, located in AstraZeneca’s U.S. headquarters in Wilmington, Delaware. He has been responsible for significant global transactions and strategic initiatives in the branded Rx, BGxand OTC areas, and has driven a wide range of commercially-focused global and regional business and corporate development evaluation, product licensing, co-commercialization and company acquisition projects.
Before joining AstraZeneca, Augustine served as a member of senior executive teams of pharmaceutical and biotechnology companies. Previously he served as Vice President of Business Development at ArchemixCorp., an aptamertherapeutic company located in Cambridge, Massachusetts. He has also held prior roles as Vice President of Business and Corporate Development at Prometheus Laboratories in San Diego, California and Senior Vice President of Corporate Development and General Counsel at Deltagenin the San Francisco Bay Area. Augustine began his career as a patent and intellectual property attorney with the U.S. law firm of Lyon and Lyon, and a corporate securities and corporate finance attorney with the international law firm of Pillsbury Winthrop, focused on representing biotech and pharmaceutical companies. He received his degree in Molecular Biology from the University of California, San Diego and his law degree magna cum laude from the Pepperdine University School of Law.